Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Beyondspring Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
BYSI
Nasdaq
8731
https://www.beyondspringpharma.com/en/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Beyondspring Inc
BeyondSpring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in a Phase 2 Investigator-initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer
- Mar 25th, 2024 11:00 am
Retail investors invested in BeyondSpring Inc. (NASDAQ:BYSI) up 125% last week, insiders too were rewarded
- Mar 6th, 2024 10:41 am
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price and Periodic Filing Requirements
- Feb 26th, 2024 1:00 pm
BeyondSpring Receives Nasdaq Delinquency Notice Regarding Late Filing of Its Form 6-K
- Jan 10th, 2024 8:00 pm
BeyondSpring Receives Nasdaq Notice Regarding Minimum Bid Price Requirements
- Dec 18th, 2023 9:30 pm
BeyondSpring Presents Poster Highlighting Preclinical and Clinical POC Immunomodulating Activity of Plinabulin Inducing Dendritic Cell Maturation and Re-sensitization in Immunotherapy Refractory Tumors when Combined with Radiation and PD-1/PD-L1 Inhibitors
- Nov 7th, 2023 12:00 pm
BeyondSpring and Professor K. Eisenmann of the University of Toledo College of Medicine Present Poster Highlighting Plinabulin’s Anti-cancer Efficacy in Primary and Recurrent Glioblastoma Patient Derived Invasive Neurosphere Models
- Oct 31st, 2023 12:00 pm
BeyondSpring Regains Compliance with Nasdaq Minimum Bid Price Requirement
- Oct 30th, 2023 12:00 pm
SEED Therapeutics Discloses Novel Molecular Glue IND Candidate for Cancer at “Targeted Protein Degradation Think Tank” Symposium
- Oct 26th, 2023 12:30 pm
SEED Therapeutics, a BeyondSpring Subsidiary, Appoints Mr. Ko-Yung Tung to the Board of Directors
- Oct 23rd, 2023 11:45 am
BeyondSpring and Leading Cancer Center to Present Poster at SITC’s 38th Annual Meeting
- Sep 27th, 2023 2:00 pm
BeyondSpring to Participate in the R.W. Baird’s 2023 Global Healthcare Conference
- Sep 7th, 2023 12:00 pm
SEED Therapeutics, BeyondSpring Subsidiary, Appoints Jackson Tai to Board of Directors
- Jun 20th, 2023 12:00 pm
BeyondSpring and Leading Cancer Center Present Poster Highlighting Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT
- Jun 7th, 2023 12:00 pm
Is BeyondSpring (NASDAQ:BYSI) In A Good Position To Invest In Growth?
- May 22nd, 2023 11:44 am
BeyondSpring and Leading Cancer Center to Present Poster at 2023 ASCO Annual Meeting
- May 18th, 2023 12:30 pm
Scroll